Table 2 Base case results for France, all anthracycline doses
| Â | Sarcoma patients | Haematological malignancy patients | ||
|---|---|---|---|---|
Usual treatment | Usual treatment + dexrazoxane | Usual treatment | Usual treatment + dexrazoxane | |
Clinical events | ||||
 Proportion with CHF (%) | 21.90 | 5.18 | 24.38 | 4.26 |
 Average age at CHF diagnosis (years) | 57.44 | 59.66 | 56.57 | 59.06 |
 Years of life with CHF | 4.90 | 1.07 | 5.45 | 0.88 |
 Number of CHF hospitalizations | 0.61 | 0.17 | 0.68 | 0.15 |
 Average age at death (years) | 68.93 | 69.00 | 67.42 | 67.55 |
Cause of death (%) | ||||
 Death from cancer | 56.38 | 57.07 | 56.12 | 57.04 |
 Cardiac death | 5.42 | 4.12 | 5.69 | 3.95 |
 Death from infection or respiratory disease | 2.62 | 2.70 | 2.60 | 2.71 |
 Death from other disease | 28.06 | 28.49 | 28.10 | 28.69 |
 Violent death | 7.52 | 7.62 | 7.49 | 7.61 |
 Death from unknown cause | 0.00 | 0.00 | 0.00 | 0.00 |
QALYs | ||||
 QALYs without cardiac disease | 18.379 | 19.593 | 18.528 | 20.099 |
 QALYs with ALVD | 1.044 | 0.681 | 1.094 | 0.500 |
 QALYs with CHF | 0.361 | 0.074 | 0.368 | 0.056 |
 Total QALYs | 19.783 | 20.349 | 19.990 | 20.654 |
 Total LY disc | 21.901 | 21.913 | 22.021 | 22.041 |
Costs (€) | ||||
 Drug and administration costs | 7080.96 | 8123.61 | 7080.96 | 8123.61 |
 Heart failure costs | 757.48 | 199.24 | 806.93 | 140.74 |
 Death costs | 4261.18 | 4252.88 | 4198.35 | 4184.70 |
 Total costs | 12,099.62 | 12,575.73 | 12,086.25 | 12,449.05 |
Incrementals | ||||
 QALYs | 0.565 |  | 0.665 |  |
 Costs (€) | 476.11 |  | 362.80 |  |
 ICER (€) | 894.55 |  | 545.87 |  |